08.01.18
Bristol-Myers Squibb
2Q Revenues: $5.7 billion (+11%)
2Q Earnings: $382.0 million (earnings were $922 million 2Q17)
YTD Revenues: $10.9 billion (+8%)
YTD Earnings: $1.9 billion (-23%)
Comments: Eliquis sales were up 40% to $474 million. Opdivo sales were $432 million, up 36%. Orencia sales were up 9% to $711 million. Sprycel sales were up 6% to $535 million. Yervoy were down 2% to $315 million. Baraclude sales were down 34% to $179 million. Sustiva Franchise sales were down 61% to $73 million. Reyataz Franchise sales were $117 million, down 38%. Hepatitis C Franchise sales were down 89% to 12 million.
2Q Revenues: $5.7 billion (+11%)
2Q Earnings: $382.0 million (earnings were $922 million 2Q17)
YTD Revenues: $10.9 billion (+8%)
YTD Earnings: $1.9 billion (-23%)
Comments: Eliquis sales were up 40% to $474 million. Opdivo sales were $432 million, up 36%. Orencia sales were up 9% to $711 million. Sprycel sales were up 6% to $535 million. Yervoy were down 2% to $315 million. Baraclude sales were down 34% to $179 million. Sustiva Franchise sales were down 61% to $73 million. Reyataz Franchise sales were $117 million, down 38%. Hepatitis C Franchise sales were down 89% to 12 million.
